LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced new results from its second human clinical study on the MindBody GLP-1 System™, revealing even more compelling outcomes across a broader participant base.
When researchers combined data from the most recent clinical trial completed in April 2025, with findings from the initial trial conducted in fall 2024, the average increase of GLP-1 improved to over 200% – a significant rise from the previously reported 140%. GLP-1 is a critical hormone that supports appetite regulation, metabolic health, and fat processing. This enhanced result further reinforces the effectiveness of the MindBody GLP-1 System in promoting sustainable, natural wellness through Activation.*‡‡
“These findings validate the effectiveness of our natural approach to stimulating the body’s own production of GLP-1 and other key metabolic hormones,”
said Lisa Barnes, Vice President of R&D and Regulatory at LifeVantage.
“The MindBody GLP-1 System and living an activated lifestyle produces meaningful, lasting results – helping people manage cravings, improve self-control, and support sustainable metabolic health naturally. We remain committed to delivering evidence-based innovations that empower health from within.*”
Key findings from LifeVantage’s U.S. clinical studies on the MindBody GLP-1 System include:
Over 200% average increase in GLP-1